戻る Agendas
ADJUVANTS IN VACCINES
Session Chair(s)
Jan Willem van der Laan, PHD
Senior Assessor Pharmacology and Toxicology
Retired From Medicines Evaluation Board, Netherlands
The last decade several vaccines have reached the market with new adjuvants. Issues have been raised about their safety, e.g., in relation to autoimmunity. The WHO took the initiative of writing a guideline on the non-clinical evaluation of vaccine adjuvants and adjuvanted vaccines. With this experience and new insights on the impact of Toll-like receptors on the immune responses, an update of the regulatory testing was needed, preferably from a global perspective. New adjuvants are still under development.
Speaker(s)
Safety of Vaccines Adjuvants with Focus on Autoimmunity: HESI workshop report
Heather L. Davis, PHD
Pfizer, Canada
Exectuvie Director
WHO Guideline on Adjuvanted Vaccines
Jan Willem van der Laan, PHD
Retired From Medicines Evaluation Board, Netherlands
Senior Assessor Pharmacology and Toxicology
Regulatory Strategy for Non-Clinical Safety Assessment to Support Malaria Candidate
Micaela Damsten, PHD
GSK Vaccines, Belgium
Manager, Nonclinical Toxicology, Global Regulatory Affairs